SS Innovations International (NASDAQ: SSII) has performed more than 15,000 procedures using its SSi Mantra robotic surgical systems, including approximately 750 cardiac procedures, CEO Dr. Sudhir Srivastava said in a recent interview with The Motley Fool. The disclosure offers investors a concrete measure of clinical adoption for a platform that is seeking to compete in the global surgical robotics market.
More than 200 telesurgeries have also been completed on the platform, including 27 cardiac procedures, as the company explores ways to extend specialist surgical expertise to underserved communities. That telesurgery capability could matter beyond the operating room: it points to a model in which scarce specialist skills are delivered remotely, potentially widening access to complex care in regions that lack on-site experts.
Srivastava highlighted the SSi Mantra's differentiated engineering, including 4K 3D visualization, surgeon-controlled anatomical imaging and a modular design supporting up to five robotic arms. Those features underpin the company's pitch that its system combines advanced capability with affordability, a combination that could lower the cost barrier for hospitals considering robotic surgery programs.
SS Innovations is preparing to expand its Indian manufacturing capacity through a planned 10-acre facility, with the objective of bringing additional production capabilities in-house. Vertical integration of manufacturing could support margin expansion and supply control as volumes rise, though the plan remains subject to execution.
Regulatory applications in Europe and the United States are also progressing, with management targeting international expansion through direct sales and opportunities in ambulatory surgery centers. Approval in those markets would substantially enlarge the addressable customer base for the platform, which currently derives its commercial traction largely from India.
Commercial momentum is already visible. First-half 2026 revenue increased approximately 66% year-over-year to about $25 million, according to the company. That growth rate, if sustained, would place SS Innovations among the faster-growing players in surgical robotics and gives management a financial base from which to fund regulatory and manufacturing expansion.
For readers following the medical device sector, the key questions are whether European and U.S. regulators will clear the SSi Mantra, whether the new Indian facility can be brought online without disrupting current production, and whether telesurgery adoption can scale beyond the roughly 200 procedures performed to date. Each of those milestones would test the durability of the company's growth story.
Additional details from the interview are available through the company's SS Innovations International (NASDAQ: SSII) profile and the full interview summary, while the latest updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. The announcement was syndicated through MissionIR, part of the Dynamic Brand Portfolio at IBN, which distributes content via InvestorWire and provides corporate communications solutions to public and private companies.
